Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials

DOI Web Site PubMed 被引用文献4件 参考文献236件
  • MINEHARU Yohei
    Division of Neuroendovascular Therapy, Institute of Biomedical Research and Innovation Departmemt of Neurosurgery, Kobe City Medical Center General Hospital
  • CASTRO Maria G
    Department of Neurosurgery, The University of Michigan School of Medicine Department of Cell and Developmental Biology, The University of Michigan School of Medicine
  • LOWENSTEIN Pedro R
    Department of Neurosurgery, The University of Michigan School of Medicine Department of Cell and Developmental Biology, The University of Michigan School of Medicine
  • SAKAI Nobuyuki
    Division of Neuroendovascular Therapy, Institute of Biomedical Research and Innovation Departmemt of Neurosurgery, Kobe City Medical Center General Hospital
  • MIYAMOTO Susumu
    Department of Neurosurgery, Kyoto University Graduate School of Medicine

この論文をさがす

抄録

High grade glioma is a highly invasive brain tumor and recurrence is almost inevitable, even after radical resection of the tumor mass. Cytotoxic immune responses and immunological memory induced by immunotherapy might prevent tumor recurrence. Dendritic cells (DCs) are professional antigen-presenting cells of the innate immune system with the potential to generate robust antigen-specific T cell immune responses. DC-based immunotherapeutic strategies have been intensively studied in both preclinical and clinical settings. Although advances have been made in the experimental use of DCs, there are still considerable challenges that need to be addressed for clinical translation. In this review, we describe the variability of regimens currently available for DC-based immunotherapy and then review strategies to optimize DC therapeutic efficacy against glioma.

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (236)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ